The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | REACH: hydroxyurea for sickle cell anemia in sub-saharan Africa
Hydroxyurea is an effective treatment for sickle cell anemia (SCA); however, the majority of studies investigating this agent have been conducted in the US and Europe, not in sub-Saharan Afria, which has the greatest burden of SCA. Here, Leon Tshilolo, MD, PhD, of Centre Hospitalier Monkole, Kinshasa, DR Congo, presents the Realizing Effectiveness Across Continents with Hydroxyurea (REACH; NCT01966731) study, a prospective, multi-national study of hydroxyurea for children with SCA in sub-Saharan Africa. These results demonstrated a wide array of benefits for daily oral hydroxyurea; with these results better access to hydroxyurea in Africa can be planned. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
